Detalhe da pesquisa
1.
Physician Payments from Pharmaceutical Companies Related to Cancer Drugs.
Oncologist
; 27(10): 857-863, 2022 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35946837
2.
Costs to Medicare of Nonrecommended Bone-Modifying Agent Use for Castration-Sensitive Prostate Cancer.
JCO Oncol Pract
; 20(3): 393-400, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38190588
3.
Pharmaceutical industry payments and delivery of non-recommended and low value cancer drugs: population based cohort study.
BMJ
; 383: e075512, 2023 10 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-37879723
4.
Real-World Use of Bone-Modifying Agents in Metastatic Castration-Sensitive Prostate Cancer.
J Natl Cancer Inst
; 114(3): 419-426, 2022 03 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-34597380
5.
Validation of a Population-Based Data Source to Examine National Cancer Clinical Trial Participation.
JAMA Netw Open
; 5(3): e223687, 2022 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35315914
6.
Effect of Financial Bonus Size, Loss Aversion, and Increased Social Pressure on Physician Pay-for-Performance: A Randomized Clinical Trial and Cohort Study.
JAMA Netw Open
; 2(2): e187950, 2019 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30735234